Enliven Therapeutics to Present Hematologic Oncology Data at SOHO Meeting
Enliven Therapeutics announced it will present clinical data on its small molecule therapeutics at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. Presentations will focus on cancer treatment development.
BURLINGAME, Calif. – Enliven Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. The company will deliver oral and poster presentations detailing its work on developing small molecule therapeutics.
The data to be presented will focus on findings from Enliven's drug candidates targeting various hematologic malignancies. New insights from the company's preclinical and clinical studies, supporting the potential of these therapies, are expected to be shared.
The SOHO Annual Meeting is a significant gathering for the hematologic oncology community, attracting leading researchers and clinicians. Enliven Therapeutics' presence at the event highlights its commitment to advancing cancer treatment research and development in the field.
The company aims to foster valuable discussions and explore potential collaborations based on the data presented. The presentations are scheduled to take place during the meeting later this year.